Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Huang

Showing results (171-180 of 179) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 179 results.
Annals of Medicine and Surgery (2012)|May 31, 2022
Recurrent appendicitis of vermiform appendix after a prior appendectomy: A case report and review of the literatureTalal Almas, Vikneswaran Raj Nagarajan, Danyal Ahmed, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
Annals of Medicine and Surgery (2012)|May 31, 2022
Candida glabrata infection of a pancreatic pseudocyst in a COVID-19 patient: A case report and review of the literatureMohammad Aasim Khan, Talal Almas, Muneeb Ullah, et al.
Gynecologic Oncology|June 8, 2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004Xiaodan Tang, Helen Huang, John D Peipert, et al.
Science (New York, N.Y.)|September 21, 2002
BLM heterozygosity and the risk of colorectal cancerStephen B Gruber, Nathan A Ellis, Karen K Scott, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
Nature Metabolism|November 9, 2023
Vitamin B<sub>5</sub> supports MYC oncogenic metabolism and tumor progression in breast cancerPeter Kreuzaler, Paolo Inglese, Avinash Ghanate, et al.
Science Translational Medicine|May 18, 2018
Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasisKevin J Frankowski, Chen Wang, Samarjit Patnaik, et al.
Pageof 18

Showing results (171-180 of 179) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 179 results.
Annals of Medicine and Surgery (2012)|May 31, 2022
Recurrent appendicitis of vermiform appendix after a prior appendectomy: A case report and review of the literatureTalal Almas, Vikneswaran Raj Nagarajan, Danyal Ahmed, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
Annals of Medicine and Surgery (2012)|May 31, 2022
Candida glabrata infection of a pancreatic pseudocyst in a COVID-19 patient: A case report and review of the literatureMohammad Aasim Khan, Talal Almas, Muneeb Ullah, et al.
Gynecologic Oncology|June 8, 2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004Xiaodan Tang, Helen Huang, John D Peipert, et al.
Science (New York, N.Y.)|September 21, 2002
BLM heterozygosity and the risk of colorectal cancerStephen B Gruber, Nathan A Ellis, Karen K Scott, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
Nature Metabolism|November 9, 2023
Vitamin B<sub>5</sub> supports MYC oncogenic metabolism and tumor progression in breast cancerPeter Kreuzaler, Paolo Inglese, Avinash Ghanate, et al.
Science Translational Medicine|May 18, 2018
Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasisKevin J Frankowski, Chen Wang, Samarjit Patnaik, et al.
Pageof 18